Building the fourth-generation AI platform for rare events risk prediction and weak signals screening in digital health

We are the fourth-generation AI designers building the first GEN-IV AI platform to characterize rare events in digital health with integrated multi-year risk prediction and early weak signals screening and detection, years before they occur.

A digital health monitoring setup displaying mobile phones and a computer screen with health data, temperature scan, and heatmap, related to prevention, medical monitoring, cancer screening, and breast cancer detection.

We started with breast cancer and we designed the first smart modular breast health digital clinic as a super-demonstrator of our integrated risk-informed GEN-IV AI Platform.

HOPE®, the first module of our smart modular breast health digital clinic, is a mobile application we launched in October 8, 2025, as a Class I CE-marked digital medical device, with registration number (01)03770040298008(8012)V1.0.6. HOPE® is available on App Store and Google Play, free of charge until October 2026. It is not a diagnostic tool and does not replace medical advice or a clinical examination by a healthcare professional. Please consult your doctor in case of doubt or unusual observation.

Before a rare event speaks, weak signals whisper

40%

of rare events in cancer or complex systems often emerge from preventable conditions linked to avoidable systemic risk factors.

40%

of rare events develop in complex systems or individuals whose increased risk potential could have been identified years earlier.

HOPE VALLEY AI transforms complex, imbalanced, multimodal and multi-physics data into predictive weak signals, enabling integrated multi-year risk prediction through trustworthy fourth-generation AI solutions capable of early detection and characterization of rare events, years before they occur.

The GEN-IV AI platform is a cross-domain technology designed to operate across multiple fields in digital health.

We started with breast cancer as our first rare event use case, as we are committed to fighting breast cancer through risk-informed prevention and early detection of its weak signals, years before it occurs.

We are following Marie Curie’s legacy from a century ago by bringing nuclear technology and innovation to the fight against cancer.

Sources: INCA, Santé Publique France, American Cancer Society, WHO, Nature Women’s Health, JRC Science for Policy Report (European Commission 2021).

What is fourth-generation AI ?

Fourth-generation Artificial Intelligence (Gen-IV AI) refers to the aggregation of an ensemble of trustworthy risk-informed and multimodal AI and Machine Learning algorithms, augmented with multi-physics methods, mathematics models, and risk engineering techniques such as imbalanced data and signals processing, uncertainties quantification and simulation, 4D-digital twin modeling, multi-year risk assessment and prediction, and safety-by-design control.

These advanced methods, models and systems are implemented to solve complex multi-scale problems with real-world integration and control optimization of operational constraints in compliance with regulatory references. It is inherently interdisciplinary, drawing on mathematics, computer science, engineering, and domain expertise. Gen-IV AI plays a key role in the digital transformation of critical sectors such as healthcare, industry, environment, and society.

Securing innovation through IP

A medical patent document with three patents related to AI-based systems for detecting early signals of cancer and other rare events in patients. The document features the logos of CEA, INRIA, and Mammope, along with a purple medical device at the bottom right.

We currently own three (3) proprietary patents, all filed in early 2025, and hold exclusive rights for all healthcare applications to a portfolio of patented technologies licensed from CEA Paris-Saclay and Inria. This portfolio includes five (5) CEA patents (filed between 2013 and 2023), the SERENA medical dataset, and Inria’s AI software platform JULIA, the latter two being protected through APP deposits submitted by Inria to INPI France.

The core patented technology was developed by Dr. Hakima BERDOUZ, Founder & CEO of Hope Valley AI, through over 15 years of cutting-edge R&D in risk engineering and artificial intelligence at CEA Paris-Saclay and the Inria Start-up Studio in Paris.

We are committed to building a high-value, strategically aligned intellectual property portfolio, with a sustained goal of filing more than five (5) patent applications per year to secure and protect our technological innovations across fourth-generation AI, risk engineering and digital health..

Proud to be backed by

Red background with white lowercase letters spelling 'cea' and a horizontal line underneath

European Union flag with 12 yellow stars in a circle on a blue background, and text that reads 'Funded by European Union'.

…and committed business angels, partners and sponsors.

Legal Mention